Published in Eur J Endocrinol on September 11, 2009
Hormone treatment and muscle anabolism during aging: androgens. Clin Nutr (2010) 0.83
Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate. Asian J Androl (2010) 0.80
Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol (2015) 0.76
Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals. Int J Endocrinol (2010) 0.76
METABOLIC EFFECTS OF HORMONE THERAPY IN TRANSGENDER PATIENTS. Endocr Pract (2015) 0.75
A sex difference in the human brain and its relation to transsexuality. Nature (1995) 2.64
Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2005) 2.60
Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med (1999) 2.13
Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev (1996) 2.11
Serum testosterone levels are not elevated in patients with ankylosing spondylitis. J Rheumatol (1998) 2.09
Transsexualism: a review of etiology, diagnosis and treatment. J Psychosom Res (1999) 2.00
Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) (1997) 1.90
Male-to-female transsexuals have female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab (2000) 1.60
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol (2008) 1.55
Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia (2008) 1.48
Birth order and sibling sex ratio in two samples of Dutch gender-dysphoric homosexual males. Arch Sex Behav (1996) 1.43
Influence of sex hormones on plasma endothelin levels. Ann Intern Med (1993) 1.40
Effects of gonadal androgens and oestrogens on adrenal androgen levels. Clin Endocrinol (Oxf) (1995) 1.40
An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav (1996) 1.38
The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med (1984) 1.36
Memory for emotional events: differential effects of centrally versus peripherally acting beta-blocking agents. Psychopharmacology (Berl) (1998) 1.31
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl (2008) 1.31
Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab (1994) 1.28
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl (2006) 1.26
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res (2008) 1.22
Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol (1999) 1.21
Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer (1999) 1.16
In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin Endocrinol Metab (2000) 1.14
Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clin Endocrinol (Oxf) (1990) 1.13
The prevalence of transsexualism in The Netherlands. Acta Psychiatr Scand (1993) 1.13
Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology (1991) 1.10
Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab (1998) 1.06
Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol (2005) 1.04
Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab (1999) 1.04
Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response. Nephrol Dial Transplant (1997) 1.04
Differences in reproductive endocrinology between Asian men and Caucasian men--a literature review. Asian J Androl (2000) 1.04
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl (2005) 1.03
Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A (1996) 1.02
Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab (1997) 1.02
Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med (1985) 1.02
5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl) (1992) 1.01
Reproducibility of fat area measurements in young, non-obese subjects by computerized analysis of magnetic resonance images. Int J Obes Relat Metab Disord (1997) 1.01
Facial corrections in male to female transsexuals: a preliminary report on 16 patients. J Oral Maxillofac Surg (1996) 1.01
Gender differences in behaviour: activating effects of cross-sex hormones. Psychoneuroendocrinology (1995) 1.00
Petrosal sinus sampling for Cushing syndrome: anatomical and technical considerations. Work in progress. Radiology (1984) 0.98
Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res (2000) 0.98
Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor. Endocrinology (2001) 0.96
Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. Metabolism (1999) 0.96
Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab (1997) 0.96
5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry (1990) 0.96
Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia (2013) 0.96
Dysregulated expression of CD66a (BGP, C-CAM), an adhesion molecule of the CEA family, in endometrial cancer. Am J Pathol (1998) 0.95
Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol (1998) 0.95
Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. Mol Cell Endocrinol (1997) 0.95
The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost (1998) 0.95
Androgens and ankylosing spondylitis: a role in the pathogenesis? Ann N Y Acad Sci (1999) 0.94
Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis (1998) 0.94
Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab (1999) 0.94
Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl (2008) 0.94
Activating effects of cross-sex hormones on cognitive functioning: a study of short-term and long-term hormone effects in transsexuals. Psychoneuroendocrinology (1999) 0.94
Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endocrinol Metab (1997) 0.93
Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr (1988) 0.91
Pituitary and adrenal responses to the anti-progesterone and anti-glucocorticoid steroid RU 486 in primates. J Clin Endocrinol Metab (1983) 0.91
Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) (1988) 0.91
Domestic violence associated with anabolic steroid abuse. Am J Psychiatry (1993) 0.90
Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh) (1987) 0.90
Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. Int J Androl (1997) 0.90
The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab (1989) 0.89
Prevalence of transsexualism in The Netherlands. Br J Psychiatry (1988) 0.89
Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology (Berl) (1991) 0.88
Arterial compliance and distensibility are modulated by body composition in both men and women but by insulin sensitivity only in women. Diabetologia (1999) 0.88
Metastatic prostatic carcinoma in a male-to-female transsexual. Br J Urol (1998) 0.88
Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab (1998) 0.88
Intravenous lipid and heparin infusion-induced elevation in free fatty acids and triglycerides modifies circulating androgen levels in women: a randomized, controlled trial. J Clin Endocrinol Metab (2008) 0.88
17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. Clin Endocrinol (Oxf) (1992) 0.88
Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab (2000) 0.88
Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol (1999) 0.88
Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab (2001) 0.87
Activating effects of androgens on cognitive performance: causal evidence in a group of female-to-male transsexuals. Neuropsychologia (1994) 0.87
NIH conference. Clinical applications of corticotropin-releasing factor. Ann Intern Med (1985) 0.87
Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab (1996) 0.87
Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans. Eur J Clin Pharmacol (1990) 0.87
Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab (2000) 0.86
Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J Clin Invest (1985) 0.86
Regulation of the human interleukin-2 gene by the alpha and beta isoforms of the glucocorticoid receptor. Mol Cell Endocrinol (1997) 0.86
Human lymphocytes produce urocortin, but not corticotropin-releasing hormone. J Clin Endocrinol Metab (1998) 0.86
Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol (Oxf) (1985) 0.86
The effects of corticotropin releasing factor on the anterior pituitary function of stalk-sectioned cynomolgus macaques: dose response of cortisol secretion. J Clin Endocrinol Metab (1982) 0.86
Structure and regulation of the human growth hormone-releasing hormone receptor gene. Mol Endocrinol (1998) 0.85
Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia (2009) 0.85
Ovine corticotropin-releasing factor administration in normal men. Pituitary and adrenal responses in the morning and evening. Horm Res (1985) 0.84
Leptin and endocrine parameters in marathon runners. Int J Sports Med (2012) 0.84
Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register. Clin Endocrinol (Oxf) (2009) 0.83
Plasma measurements of corticotrophin-releasing hormone-binding protein in normal and abnormal human pregnancy. J Endocrinol (1993) 0.83
A multihormonal response to corticotropin-releasing hormone in inferior petrosal sinus blood of patients with Cushing's disease. J Clin Endocrinol Metab (1990) 0.83
Expression patterns of the cell-cycle inhibitor p27 and the cell-cycle promoter cyclin E in the human placenta throughout gestation: implications for the control of proliferation. Placenta (1999) 0.83
The corticotropin-releasing hormone stimulation test: a possible aid in the evaluation of patients with adrenal insufficiency. J Clin Endocrinol Metab (1984) 0.83
Allogenic bone marrow transplantation in adults: endocrine sequelae after 1-6 years. Acta Endocrinol (Copenh) (1989) 0.83
High-dose progesterone infusion in healthy males: evidence against antiglucocorticoid activity of progesterone. Eur J Endocrinol (1995) 0.83
Expression of steroidogenic factor-1 (SF-1) mRNA and protein in the human placenta. Mol Hum Reprod (1996) 0.83
Haemodialysis and testicular function. Int J Androl (1984) 0.83
Subsensitivity of the 5-hydroxytryptamine1A (5-HT1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Sci (1990) 0.83
Brain research, gender and sexual orientation. J Homosex (1995) 0.83
Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonists. J Clin Endocrinol Metab (1990) 0.82
Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism (1989) 0.82